Fabian Raschke Appointed Chief Financial Officer (CFO) (FOTO)

Aachen (ots) -

Grünenthal announced today that Fabian Raschke has been appointed
Chief Financial Officer (CFO) and Member of the Corporate Executive
Board. He will assume leadership of Grünenthal's Finance and IT
organisation on 1 February 2019. Fabian currently leads Grünenthal's
Group Controlling and manages over 150 employees, including Finance
staff in the affiliates.

Fabian is a senior executive with extensive experience in all
aspects of finance and its interfaces, especially related to mergers
& acquisitions, integrations, IPO preparations and placements of
bonds on the capital market. He graduated in Economics and held roles
with increasing levels of responsibility within the Xella Group
(formerly part of Haniel) during his career before joining Grünenthal
in September 2016. Fabian is a German national. He is married and has
three children.

"I'm delighted to welcome Fabian to the Corporate Executive Board.
Throughout his career, he has proven his ability to lead finance
organisations towards success and has played a major role in our key
milestones such as securing the financing for our recent acquisition
of Nexium® and Vimovo®," said Gabriel Baertschi, CEO Grünenthal.

"We look forward to collaborating even more closely with Fabian.
He is a highly skilled leader who will make major contributions to
Grünenthal's positive development. Since joining Grünenthal, Fabian
has already significantly improved our financial instruments and
initiated the digitalisation of our Finance function," said Wilhelm
Moll, Chairman of the Grünenthal Supervisory Board.

"I'm very pleased about the trust placed in me by Grünenthal's
shareholders and my colleagues in the Corporate Executive Board. I
look forward to seizing this opportunity and making an even stronger
contribution to Grünenthal's vision of creating a world free of pain
for patients in need," Fabian Raschke added.

About Grünenthal

Grünenthal is an entrepreneurial, science-based pharmaceutical
company specialized in pain, gout and inflammation. Our ambition is
to deliver four to five new products to patients in diseases with
high unmet medical need by 2022 and become a EUR 2 bn company. We are
a fully integrated research & development company with a long track
record of bringing innovative pain treatments and state-of-the-art
technologies to patients. By sustainably investing in our R&D above
the industrial average, we are strongly committed to innovation.

Grünenthal is an independent, family-owned company headquartered
in Aachen, Germany. We are present in approx. 30 countries with
affiliates in Europe, Latin America and the US. Our products are sold
in more than 100 countries and approx. 5,200 employees are working
for Grünenthal worldwide. In 2017, Grünenthal achieved revenues of
approx. EUR 1.3 bn.

More information: www.grunenthal.com

Follow us on:
LinkedIn: Grunenthal Group
Twitter: @grunenthalgroup
Instagram: gruenenthal

For further information, please contact:
Stepan Kracala, Head Global Communications
Tel.: +49 241 569-1335, Stepan.Kracala@grunenthal.com
Grünenthal GmbH, 52099 Aachen, Germany

Kerstin Nacken, Head Editorial Management and Media Relations
Tel.: +49 241 569-2710, Kerstin.Nacken@grunenthal.com
Grünenthal GmbH, 52099 Aachen, Germany

Original-Content von: Grünenthal Group, übermittelt durch news aktuell